Who we are

  • Inbiose is a leading B2B Biotech Company with focus on the development of specialty glycans, in particular Human Milk Oligosaccharides (HMOs)

  • We have a proven track record in developing cost-effective processes for large scale HMO production, based on our proprietary GlycoActives® technology

  • What was started in 2013 as a spinoff from the University of Ghent, we are now the biggest private research group in the world of specialty glycans. 


Our focus

  • Inbiose is dedicated to developing specialty glycans that are known to influence health, either directly or indirectly through modulation of the microbiome.

  • We continuously improve our technology platform based on latest advancements into biotech, bio-informatics and health sciences.

  • We strive to make these specialty glycans  available for

    mainstream uses, minimizing time to market, to the benefit of all.


Our story

Following some scientific breakthroughs demonstrating the potential to efficiently manufacture specialty glycans using white biotechnology, Inbiose origin is at the University of Ghent-Belgium, where it was founded in 2013.

Since then, the company has grown consistently and we’re proud to have build a team of 50 highly skilled and committed, mainly bio-engineers and bio-informatics.

Inbiose has its offices and lab in the Technology Park in Ghent-Belgium, which is second largest Biotech hub in the world.

Leading the way in specialty carbohydrates